{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:18:53Z","timestamp":1773465533074,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>New antivirals are urgently needed to treat respiratory diseases caused by RNA viruses [...]<\/jats:p>","DOI":"10.3390\/ijms241210315","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:31:14Z","timestamp":1687138274000},"page":"10315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antivirals and Vaccines"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0176-5585","authenticated-orcid":false,"given":"Nuno","family":"Taveira","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"},{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz (CiiEM), Egas Moniz School of Health and Science, Campus Universit\u00e1rio, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: Past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14787210.2019.1635009","article-title":"Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool","volume":"17","author":"Adalja","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fcimb.2018.00398","article-title":"Cellular Targets for the Treatment of Flavivirus Infections","volume":"8","author":"Zakaria","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Setz, C., Grosse, M., Auth, J., Froba, M., Rauch, P., Bausch, A., Wright, M., and Schubert, U. (2022). Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126830"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104673","DOI":"10.1016\/j.micpath.2020.104673","article-title":"The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options","volume":"150","author":"Choudhary","year":"2021","journal-title":"Microb. Pathog."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Thaler, M., Salgado-Benvindo, C., Leijs, A., Tas, A., Ninaber, D.K., Arbiser, J.L., Snijder, E.J., and van Hemert, M.J. (2023). R-Propranolol Has Broad-Spectrum Anti-Coronavirus Activity and Suppresses Factors Involved in Pathogenic Angiogenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054588"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/CCID.S332625","article-title":"Propranolol in the Treatment of Infantile Hemangiomas","volume":"14","author":"Tan","year":"2021","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2003147","DOI":"10.1183\/13993003.03147-2020","article-title":"Inflammation and intussusceptive angiogenesis in COVID-19: Everything in and out of flow","volume":"56","author":"Ackermann","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Subedi, S., Koirala, S., and Chai, L. (2021). COVID-19 in Farm Animals: Host Susceptibility and Prevention Strategies. Animals, 11.","DOI":"10.3390\/ani11030640"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26915","DOI":"10.1073\/pnas.2001046117","article-title":"Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection","volume":"117","author":"Edwards","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12250-020-00321-3","article-title":"Broad Cell Tropism of SADS-CoV In Vitro Implies Its Potential Cross-Species Infection Risk","volume":"36","author":"Luo","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, Y., You, Y., Wang, S., Jiang, L., Tian, L., Zhu, S., An, X., Song, L., Tong, Y., and Fan, H. (2022). Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911250"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jang, Y., Shin, J.S., Lee, M.K., Jung, E., An, T., Kim, U.I., Kim, K., and Kim, M. (2021). Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041581"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/1348-0421.12828","article-title":"Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2","volume":"64","author":"Kato","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106202","DOI":"10.1016\/j.ijantimicag.2020.106202","article-title":"Methylene blue inhibits replication of SARS-CoV-2 in vitro","volume":"56","author":"Gendrot","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2200148","DOI":"10.1002\/adbi.202200148","article-title":"Cepharanthine: A Promising Old Drug against SARS-CoV-2","volume":"6","author":"Fan","year":"2022","journal-title":"Adv. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.lansea.2023.100154","article-title":"Safety and efficacy of mycophenolate in COVID-19: A nonrandomised prospective study in western India","volume":"11","author":"Sajgure","year":"2023","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112023","DOI":"10.1016\/j.biopha.2021.112023","article-title":"Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations","volume":"142","author":"Dabholkar","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wedekind, S.I.S., and Shenker, N.S. (2021). Antiviral Properties of Human Milk. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040715"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3945\/jn.116.246090","article-title":"Milk Oligosaccharides Inhibit Human Rotavirus Infectivity in MA104 Cells","volume":"147","author":"Laucirica","year":"2017","journal-title":"J. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41467-018-07476-4","article-title":"Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection","volume":"9","author":"Ramani","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1017\/S0007114508025804","article-title":"Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN)","volume":"101","author":"Hong","year":"2009","journal-title":"Br. J. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lou, F., Hu, R., Chen, Y., Li, M., An, X., Song, L., Tong, Y., and Fan, H. (2022). 2\u2019-Fucosyllactose Inhibits Coxsackievirus Class A Type 9 Infection by Blocking Virus Attachment and Internalisation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213727"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.3390\/v7122945","article-title":"Infectious Entry Pathway of Enterovirus B Species","volume":"7","author":"Turkki","year":"2015","journal-title":"Viruses"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","article-title":"The life cycle of non-polio enteroviruses and how to target it","volume":"16","author":"Baggen","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hope, T.J., Stevenson, M., and Richman, D. (2016). Encyclopedia of AIDS, Springer.","DOI":"10.1007\/978-1-4614-9610-6"},{"key":"ref_27","unstructured":"UNAIDS (2016). Fact Sheet\u2014Latest Statistics on the Status of the AIDS Epidemic, UNAIDS."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/S2352-3018(18)30254-6","article-title":"Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: A prospective open cohort study","volume":"6","author":"Esbjornsson","year":"2018","journal-title":"Lancet HIV"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1097\/00002030-200312050-00006","article-title":"Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort","volume":"17","author":"Matheron","year":"2003","journal-title":"AIDS"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/fvl-2017-0037","article-title":"Antiretroviral treatment of HIV-2 infection","volume":"12","author":"Requena","year":"2017","journal-title":"Future Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11013","DOI":"10.1073\/pnas.1832214100","article-title":"A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding","volume":"100","author":"Lin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1021\/jm034082o","article-title":"Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions","volume":"46","author":"Wang","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dkp216","article-title":"Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1\/2 and HIV-2 seropositive West Africans: A retrospective study","volume":"64","author":"Sarfo","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/QAD.0b013e3283377a06","article-title":"First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration","volume":"24","author":"Drylewicz","year":"2010","journal-title":"AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1128\/AAC.00154-09","article-title":"Antiretroviral drug resistance in human immunodeficiency virus type 2","volume":"53","author":"Ntemgwa","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/infdis\/jiaa026","article-title":"Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2","volume":"221","author":"Tzou","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Moranguinho, I., Taveira, N., and Bartolo, I. (2023). Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065905"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Khare, B., and Kuhn, R.J. (2022). The Japanese Encephalitis Antigenic Complex Viruses: From Structure to Immunity. Viruses, 14.","DOI":"10.3390\/v14102213"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1128\/JVI.02686-13","article-title":"Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia","volume":"88","author":"Schuh","year":"2014","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1039\/D0CS01118E","article-title":"Antiviral drug discovery: Preparing for the next pandemic","volume":"50","author":"Adamson","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Li, C., Chen, X., Hu, J., Jiang, D., Cai, D., and Li, Y. (2022). A Recombinant Genotype I Japanese Encephalitis Virus Expressing a Gaussia Luciferase Gene for Antiviral Drug Screening Assay and Neutralizing Antibodies Detection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415548"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ymthe.2004.10.016","article-title":"Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo","volume":"11","author":"Tannous","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4269\/ajtmh.1957.6.1012","article-title":"Mayaro virus: A new human disease agent. II. Isolation from blood of patients in Trinidad, B.W.I","volume":"6","author":"Anderson","year":"1957","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Levi, L.I., and Vignuzzi, M. (2019). Arthritogenic Alphaviruses: A Worldwide Emerging Threat?. Microorganisms, 7.","DOI":"10.3390\/microorganisms7050133"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Diagne, C.T., Bengue, M., Choumet, V., Hamel, R., Pompon, J., and Miss\u00e9, D. (2020). Mayaro Virus Pathogenesis and Transmission Mechanisms. Pathogens, 9.","DOI":"10.3390\/pathogens9090738"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kim, Y.C., Lucke, A.C., Lopez-Camacho, C., Kummerer, B.M., and Reyes-Sandoval, A. (2022). Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084105"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:04Z","timestamp":1760126164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms241210315"],"URL":"https:\/\/doi.org\/10.3390\/ijms241210315","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}